News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280 Results
Type
Article (5)
Press Release (275)
Section
Business (92)
Deals (15)
Drug Development (69)
Job Trends (1)
News (155)
Policy (4)
Tag
Academia (1)
Alliances (10)
Alzheimer's disease (1)
Clinical research (56)
COVID-19 (2)
Data (1)
Earnings (49)
Events (62)
Healthcare (1)
Infectious disease (2)
IPO (13)
Job creations (1)
Mergers & acquisitions (2)
Neuroscience (1)
People (24)
Phase 1 (11)
Phase 2 (35)
Phase 3 (19)
Pipeline (1)
Postmarket research (1)
Preclinical (6)
Real estate (1)
Regulatory (4)
Date
2024 (5)
2023 (17)
2022 (29)
2021 (30)
2020 (40)
2019 (6)
2018 (5)
2017 (26)
2016 (23)
2015 (37)
2014 (26)
2013 (10)
2012 (7)
2011 (5)
2010 (3)
280 Results for "erytech".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
ERYTECH Provides Update on the Announced Combination with PHERECYDES
ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided anupdateon the announced combination with PHERECYDES.
May 15, 2023
·
9 min read
Deals
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).
June 26, 2023
·
7 min read
Business
ERYTECH Provides Business and Financial Update for the First Quarter of 2023
ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial updatefor thefirst quarter of 2023.
May 9, 2023
·
10 min read
Genetown
ERYTECH Provides Regulatory Update
ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia following feedback from the U.S. Food and Drug Administration.
August 24, 2022
·
6 min read
Policy
ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market
ERYTECH Pharma dated April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.
April 17, 2023
·
5 min read
Genetown
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
ERYTECH Pharma announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.
June 5, 2023
·
1 min read
Business
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
ERYTECH Pharma (Nasdaq & Euronext: ERYP) today provided a business and financial update for the fourth quarter and full year of 2022.
March 22, 2023
·
11 min read
Genetown
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
ERYTECH Pharma announced the availability of the documents for its Annual General Meeting to be held on Friday, June 23, 2023.
May 24, 2023
·
2 min read
Genetown
ERYTECH announces that the Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma
ERYTECH Pharma, announced that the Lyon Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma.
June 14, 2023
·
4 min read
Drug Development
Erytech Abandons BLA Plans for Leukemia Drug, Citing Competitive Market
Erytech Pharma is abandoning plans to submit a Biologics License Application to the FDA for Graspa in hypersensitive acute lymphoblastic leukemia.
August 25, 2022
·
2 min read
·
Mark Terry
1 of 28
Next
